Cross-Reactive Immune Response Induced by the Vi Capsular Polysaccharide Typhoid Vaccine AgainstSalmonellaParatyphi Strains

Autor:	Sari H. Pakkanen, Anu Kantele, Jussi M. Kantele
Rok vydání:	2014
Předmět:	Adult Male Ty21a 030231 tropical medicine Immunology Cross Reactions ta3111 Salmonella typhi complex mixtures Typhoid fever Microbiology Young Adult 03 medical and health sciences fluids and secretions 0302 clinical medicine Antigen Paratyphoid Fever Humans Medicine 030304 developmental biology 0303 health sciences Vi capsular polysaccharide vaccine business.industry Polysaccharides Bacterial Typhoid-Paratyphoid Vaccines Vaccination Paratyphoid fever Salmonella paratyphi A O Antigens General Medicine Middle Aged medicine.disease Antibodies Bacterial Virology 3. Good health Salmonella paratyphi B Salmonella paratyphi C bacteria Female Bacterial antigen business medicine.drug
Zdroj:	Scandinavian Journal of Immunology. 79:222-229
ISSN:	0300-9475
DOI:	10.1111/sji.12151
Popis:	There are no vaccines in clinical use against paratyphoid fever, caused by Salmonella Paratyphi A and B or, rarely, C. Oral Salmonella Typhi Ty21a typhoid vaccine elicits a significant cross-reactive immune response against S. Paratyphi A and B, and some reports suggest cross-protective efficacy against the disease. These findings are ascribed to the O-12 antigen shared between the strains. The Vi capsular polysaccharide vaccine has been shown to elicit antibodies reactive with O-9,12. Twenty-five volunteers immunized with the parenteral Vi vaccine (Typherix(®) ) were explored for plasmablasts cross-reactive with paratyphoid strains; the responses were compared to those in 25 age- and gender-matched volunteers immunized with Ty21a (Vivotif(®) ). Before vaccination, 48/50 vaccinees had no plasmablasts reactive with the antigens. Seven days after vaccination, 15/25 and 22/25 Vi- and Ty21a-vaccinated volunteers had circulating plasmablasts producing antibodies cross-reactive with S. Paratyphi A, 18/25 and 23/25 with S. Paratyphi B and 16/25 and 9/25 with Paratyphi C, respectively. Compared to the Ty21a group, the Vi group showed significantly lower responses to S. Paratyphi A and B and higher to S. Paratyphi C. To conclude, the Vi vaccine elicited a cross-reactive plasmablast response to S. Paratyphi C (Vi antigen in common) and less marked responses to S. Paratyphi A and B than the Ty21a preparation. S. Paratyphi A and B both being Vi-negative, the result can be explained by trace amounts of bacterial cell wall O-12 antigen in the Vi preparation, despite purification. The clinical significance of this finding remains to be determined.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3eec16fe95e91f1b660581784d6b42 https://doi.org/10.1111/sji.12151 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.